Home
Clinical Trials
Paraneoplastic Neurological S...

Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis Collection

NCT ID: NCT05198661

Last Updated: 2024-02-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

Total Enrollment

3500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-02

Study Completion Date

2032-08-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Numerous neurological disorders affecting the central and peripheral nervous system can be attributed to the immune system through multiple effector mechanisms. However, current treatments could be drastically improved by faster and more accurate diagnosis. The sample collection will benefit to patients with rare neuroimmune syndromes such as Autoimmune Encephalitis (AE) and Paraneoplastic Neurological Syndromes (PNS) leading to a better and early diagnosis, as well as treatment improvement.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Collection of Biological Samples from Patients with Rare Neurological Diseases

NCT04698421

Nervous System Diseases

RECRUITING

Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden

NCT04708626

Autoimmune Encephalitis Paraneoplastic Neurological Syndrome

COMPLETED

Tongji NADs Cohort

NCT07333196

Multiple Sclerosis NMO Spectrum Disorder Autoimmune Encephalitis +6 more

NOT_YET_RECRUITING

Biomarkers in Autoimmune Disease of Nervous System

NCT06502015

Autoimmune Diseases of the Nervous System Neuromyelitis Optica Spectrum Disorder Multiple Sclerosis +8 more

RECRUITING

Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis

NCT05177939

Autoimmune Encephalitis

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Paraneoplastic Neurological Syndromes or Autoimmune Encephalitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

Intervention Model

SINGLE_GROUP

Blood sample

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Paraneoplastic neurological syndrome patients and autoimmune encephalitis patient

patients with diagnosis of paraneoplastic neurological syndrome or autoimmune encephalitis

Group Type OTHER

Collection of biological sample with sera, CSF, buffy coat, PBMC, plasma.

Intervention Type BIOLOGICAL

Blood is collected only one time by blood sample to obtain serum, buffy coat, plasma and PBMC.

2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube If possibility of delivery in 48 hours at the Centre of Biological Resources, 7\*4ml of blood on heparin tube If cerebrospinal fluid has been drawn for diagnosis, remaining sample available will be stored in the collection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Collection of biological sample with sera, CSF, buffy coat, PBMC, plasma.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with consent
* Patient with well-characterized antibodies in serum or cerebrospinal fluid or not
* Patient with neurological disorder compatible with PNS or auto-immune encephalitis

Exclusion Criteria

* Refusal of consent
* Patient under guardianship

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.